HomeInsightsPE

Shilpa Medicare Ltd PE Ratio

Shilpa Medicare Ltd PE Ratio

stocks purchased

₹ 1.6 Cr

Volume transacted

stocks purchased

20.5 K

stocks traded

Last Updated time: 04 Oct 15:30 PM

Image

Shilpa Medicare Ltd

NSE: SHILPAMED

PE

191.9

Last updated: 04 Oct 15:30 PM

Key Highlights

  • The P/E Ratio of Shilpa Medicare Ltd is 191.9 as of 04 Oct 15:30 PM.
  • The P/E Ratio of Shilpa Medicare Ltd changed from 24.7 on March 2019 to 125.7 on March 2024 . This represents a CAGR of 31.15% over 6 years. .
  • The Latest Trading Price of Shilpa Medicare Ltd is ₹ 802.9 as of 04 Oct 15:30.
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 21.8. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 158.1. The PE Ratio of Textiles industry is 37.6. In 2024.

Historical P/E Ratio of Shilpa Medicare Ltd

No data available

Company Fundamentals for Shilpa Medicare Ltd

No data available

Image

Shilpa Medicare Ltd

NSE: SHILPAMED

PRICE

802.9

-3.00 (-0.37%)

stock direction

Last updated: 04 Oct 15:30

Share price Over Time

1M

1Y

3Y

5Y

Monitoring Shilpa Medicare Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Share Price

Date
leftPriceleft
03 Oct 2024805.9
01 Oct 2024834.65
30 Sep 2024813.45
27 Sep 2024808
26 Sep 2024844.7
25 Sep 2024843.7
24 Sep 2024834.65
23 Sep 2024856.65
20 Sep 2024867.15
19 Sep 2024847.35

SWOT Analysis Of Shilpa Medicare Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Shilpa Medicare Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Shilpa Medicare Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Shilpa Medicare Ltd1917,880
Sun Pharmaceuticals Industries Ltd434,59,137
Divis Laboratories Ltd861,44,115
Cipla Ltd301,33,733
Torrent Pharmaceuticals Ltd681,14,735
Dr Reddys Laboratories Ltd201,12,387

Key Valuation Metric of Shilpa Medicare Ltd

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Shilpa Medicare Ltd

No data available

* All values are in crore

Historical Revenue of Shilpa Medicare Ltd

No data available

* All values are in crore

Historical EBITDA of Shilpa Medicare Ltd

No data available

* All values are in crore

Historical Net Profit of Shilpa Medicare Ltd

No data available

* All values are in crore

Historical Dividend Payout of Shilpa Medicare Ltd

No data available

* All values are in %

About Shilpa Medicare Ltd

  • Shilpa Medicare Limited (formerly known as Shilpa Antibiotics Limited) was incorporated as a Private Limited Company in November 20th, 1987 and has been promoted by Vishnukant C Bhutada and his associates.
  • Shilpa Medicare Limited (SML) is engaged in manufacturing of Active Pharmaceutical Ingredients (API), Formulation and Development service.
  • The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
  • The company started commercial production in November 1989.
  • In November 1993, Shilpa Medicare Limited was converted into a Public Limited Company.

Shilpa Medicare Ltd News Hub

News

Shilpa Medicare arm gets CEP from EDQM for Desmopressin

Desmopressin is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid...

Read more

04 Oct 202408:40

News

Shilpa Medicare announces receipt of CEP from EDQM for API 'Desmopressin'

Shilpa Medicare's 100% subsidiary, Shilpa Pharma Lifesciences received certificate of suit...

Read more

03 Oct 202417:12

News

Shilpa Biologicals appoints CEO

Shilpa Medicare announced the appointment of Dr. Sridevi Khambhampaty, as Chief Executive ...

Read more

19 Sep 202413:35

News

Shilpa Medicare arm appoints Sridevi Khambhampaty as CEO

Sridevi Khambhampaty y is a recognized leader in the Biologics industry with over two deca...

Read more

19 Sep 202413:35

News

Shilpa Medicare update on its CDMO customer - Unicycive Therapeutics

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) announced the submission of NDA to U.S. FDA fo...

Read more

04 Sep 202415:14

News

Shilpa Medicare hits life high on submission of new drug application to USFDA

The said drug is used for treatment of hyperphosphatemia in patients with chronic kidney d...

Read more

04 Sep 202415:24

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

FAQs for PE of Shilpa Medicare Ltd

What is the current PE Ratio of Shilpa Medicare Ltd?

The Current PE Ratio of Shilpa Medicare Ltd is 191.88 as on 4 Oct 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 4 Oct 2024.

What was the PE Ratio of Shilpa Medicare Ltd last year?

The PE Ratio of Shilpa Medicare Ltd was 0.0 last year, now the PE ratio is 191.88, showing a year-on-year growth of -%.

What does the PE Ratio of Shilpa Medicare Ltd indicate about its stock?

The PE Ratio of Shilpa Medicare Ltd is 191.88. This ratio indicates that investors are willing to pay 191.88 times the earnings per share for each share of Shilpa Medicare Ltd.

What is the PE Ratio Growth of Shilpa Medicare Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Shilpa Medicare Ltd grew by -% whereas, the EPS ratio grew by -48.2.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*